Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Berberine · 1 trial · 3 indications
Assessments will be conducted at baseline and once every three weeks thereafter.
| Arm | Type | Description |
|---|---|---|
| Berberine | ACTIVE_COMPARATOR | Patients will receive berberine pills in additional to current atypical antipsychotic agents |
| Placebo | PLACEBO_COMPARATOR | Patients will receive placebos pills in additional to current atypical antipsychotic agents |
| Name | Type | Description |
|---|---|---|
| Berberine | DRUG | Berberine tablets, 0.3g every time, two times daily |
| Placebos | DRUG | Placebo tablets, 0.3g every time, two times daily |
| Antipsychotic Agents | DRUG | Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study. |
Inclusion Criteria: * a primary diagnosis of SSD, including schizophrenia, schizoaffective disorder, schizophreniform disorder, and psychotic disorder not otherwise specified according to the Classification of Mental and Behavior Disorders (10th version); * have been under atypical antipsychotic tr...